Results from a recently conducted animal study show that psilocybin may be effective in decreasing weight gain in obese subjects. Psilocybin is the psychoactive compound found in hallucinogenic mushrooms. Based on prior findings, researchers believe that the compound could be useful in the treatment of various mental health indications, especially when administered in conjunction with therapy.
This particular study was carried out by NeonMind Biosciences, an integrated psychedelic drug development and wellness firm. The firm had in the recent past concluded similar research, which found that the psychedelic decreased weight gain in healthy animal subjects.
The psychedelic drug company used its version of psilocybin for the research, leading to the discovery that the compound had the ability to target and reduce visceral fat, resulting in better overall health outcomes in these obese animals. This is important because increased visceral fat has been associated with poorer cardiometabolic health.
The company also found that the compound’s effectiveness was observed within days of its administration and that there were no negative safety signals. In addition to this, NeonMind observed decreased consumption of food in the obese group, especially in comparison to the control group.
While the study has found that psilocybin may be an effective and safe medicine to decrease weight gain in animal subjects, the same may not be said for humans until similar trials are carried out. The company intends to use the data from this particular trial to advance its pair of proprietary compounds of psilocybin, NEO-001 and NEO-002, through the development pipeline. It hopes that either or both of the versions will progress to phase I clinical trials. The study is yet to be published. Currently, its findings are being reviewed by a leading industry peer-reviewed journal.
NeonMind isn’t the only company working with psychedelics to treat eating disorders. For instance, Tryp Therapeutics recently begun recruiting participants for its phase II trial, which will test the effectiveness of its psilocybin compound, TRP-8802, in the treatment of binge eating disorder.
Jim Gilligan, Tryp Therapeutics’ interim CEO, stated that the aim of its clinical trial was to confirm that its version of psilocybin could help forge healthy neural connections that addressed the unhealthy eating behaviors of patients with this indication. Individuals with binge eating disorder usually feel unable to stop eating and consume unusually large amounts of food.
Additionally, Compass Pathways is also planning to carry out a phase II clinical trial assessing the effectiveness of its COMP-360 psilocybin formulation in the treatment of anorexia nervosa. Other companies, including Delic Holdings Corp. (CSE: DELC) (OTC: DELCF), are focused on developing technology to vaporize psilocybin medicine, among other aspects of interest.
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.